The largest community for pharma industry writers and readers

JOIN 2020 TPMG ONLINE PHARMA SUMMIT

CALL FOR AUTHOR - 2020 FEATURED WRITERS

RESEARCH AND DEVELOPMENT


Newsletter

RESEARCH AND DEVELOPMENT from The Pharmaceutical Marketing Group is a regular email newsletter with news about research and development from the pharmaceutical industry

Direct to your inbox

Stay up to date with the latest appointments by subscribing to RESEARCH AND DEVELOPMENT! from The Pharmaceutical Marketing Group

View the newsletter archive

Research and Development

NeuClone Announces Completion of Subject Visits in Stelara® (ustekinumab) Biosimilar Phase I Clinical Trial

Admin -
SYDNEY--(BUSINESS WIRE)--NeuClone Pharmaceuticals Ltd (NeuClone), a clinical-stage biopharmaceutical company...
Read more
Research and Development

AIVITA Biomedical Provides Update of Ongoing Phase 2 Glioblastoma Trial from Year-End Survival Analysis

Admin -
IRVINE, Calif.--(BUSINESS WIRE)--AIVITA Biomedical, Inc., a biotechnology company specializing...
Read more
Research and Development

BELLUS Health Announces Completion of Dosing in Phase 2 RELIEF Trial with BLU-5937 for the Treatment of Refractory Chronic Cough

Admin -
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU)...
Read more
Research and Development

Can-Fite Reports Positive Top Line Results from its Phase II NASH Study with Namodenoson

Admin -
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF)...
Read more
Research and Development

Millendo Therapeutics Announces Topline Results for Pivotal Phase 2b Study of Livoletide in Patients with Prader-Willi Syndrome (PWS)

Admin -
ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a...
Read more
Research and Development

The Lancet Simultaneously Publishes Two Phase 3 Studies Detailing Comprehensive Efficacy and Safety of TREMFYA®▼ (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, in Psoriatic...

Admin -
BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson &...
Read more
Research and Development

Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium

Admin -
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced the first...
Read more
Research and Development

Jichi Medical University and CureApp, Inc.: The First Phase 3 Clinical Trials of "Digital Therapeutics" for Hypertension Begin in Japan

Admin -
TOKYO--(BUSINESS WIRE)--CureApp, Inc. (Head Office, Chuo-ku, Tokyo; President and...
Read more
Research and Development

UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer

Admin -
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN) announced positive interim...
Read more
Research and Development

Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25 in First-Line HER2-Positive Breast Cancer and Gastroesophageal Adenocarcinoma Conducted by BeiGene

Admin -
VANCOUVER--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company...
Read more
Research and Development

As Part of a Global Partnership with Nestlé Health Science, VALBIOTIS Initiates the Pivotal Late Stage Development Phase of TOTUM-63, a Plant-Derived Active Substance...

Admin -
LA ROCHELLE, France--(BUSINESS WIRE)--Regulatory News: VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL...
Read more
Research and Development

NOXXON Announces Completion of Patient Recruitment for the First Dose Cohort in the Phase 1/2 Brain Cancer Study Of NOX-A12 Plus Radiotherapy

Admin -
BERLIN--(BUSINESS WIRE)--Regulatory News: NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth...
Read more

Receive our newsletters

Get In Touch

All Rights Reserved

The Pharmaceutical Marketing Group